Stocks trading below cash value on the NAS December 2025

December 12, 2025

Below Cash Value

Companies are trading below cash value when their current share price is less than the cash per share on their balance sheet or with more cash than market cap. Companies can have more cash per share than the actual share price for a number of reasons, including that they just raised capital, are in industries that experience high burn rates, or there is a lot of uncertainty about the future of the company.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

About the Data

This table includes companies whose current share price is less than the cash per share on their balance sheet or stocks with more cash than market cap. We also include the value of cash net debt per share to show how much cash per share would be left if the debt was paid off.

How do you use this table?

Stocks on this list have potential for higher reward and risk. It is imperative to understand why these companies are trading at less than cash value. Stocks in this category are generally held for speculation or growth.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

Symbol Name Close Price Shares Outstanding P/E P/B Cash per Share Net Cash per Share
ACON Aclarion Inc 7.45 582371 - - 25.33 0.68
ADAP Adaptimmune Therapeutics Plc 0.05 265051591 - - 0.15 -0.03
ALGS Aligos Therapeutics Inc 10.88 6114801 - - 12.06 10.78
ALZN Alzamend Neuro Inc 2.40 733056 - - 4.58 0.10
AMCX AMC Networks Inc 7.98 44927278 - - 19.37 -34.50
AMIX Autonomix Medical, Inc. Common Stock 1.16 2462983 - - 3.71 4.34
APLM Apollomics Inc. Class A Ordinary Shares 6.27 1103348 - - 8.85 7.98
APLMW Apollomics Inc. Class A Ordinary Shares 0.03 89480790 - - 0.11 0.10
APRE Aprea Therapeutics Inc 1.57 5531373 - - 3.48 5.20
APVO Aptevo Therapeutics Inc 1.50 675000 - - 3.17 -3.38
All data provided as at market close September 10, 2025.

Company Details

Aclarion Inc

ACON:NAS

Shares Outstanding

582371

Cash per Share

25.33

Net Cash per Share

0.68

Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.

Access the stockcalc valuation


Adaptimmune Therapeutics Plc

ADAP:NAS

Shares Outstanding

265051591

Cash per Share

0.15

Net Cash per Share

-0.03

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.

Access the stockcalc valuation


Aligos Therapeutics Inc

ALGS:NAS

Shares Outstanding

6114801

Cash per Share

12.06

Net Cash per Share

10.78

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

Access the stockcalc valuation


Alzamend Neuro Inc

ALZN:NAS

Shares Outstanding

733056

Cash per Share

4.58

Net Cash per Share

0.10

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

AMC Networks Inc

AMCX:NAS

Shares Outstanding

44927278

Cash per Share

19.37

Net Cash per Share

-34.50

AMC Networks Inc., an entertainment company, distributes contents in the United States, Europe, and internationally. The company operates through two segments Domestic Operations and International.

Access the stockcalc valuation


Autonomix Medical, Inc. Common Stock

AMIX:NAS

Shares Outstanding

2462983

Cash per Share

3.71

Net Cash per Share

4.34

Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.

Access the stockcalc valuation


Apollomics Inc. Class A Ordinary Shares

APLM:NAS

Shares Outstanding

1103348

Cash per Share

8.85

Net Cash per Share

7.98

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.

Access the stockcalc valuation


Apollomics Inc. Class A Ordinary Shares

APLMW:NAS

Shares Outstanding

89480790

Cash per Share

0.11

Net Cash per Share

0.10

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.

Access the stockcalc valuation


Aprea Therapeutics Inc

APRE:NAS

Shares Outstanding

5531373

Cash per Share

3.48

Net Cash per Share

5.20

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.

Access the stockcalc valuation


Aptevo Therapeutics Inc

APVO:NAS

Shares Outstanding

675000

Cash per Share

3.17

Net Cash per Share

-3.38

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Aclarion and Adaptimmune Therapeutics on the NAS were trading below cash value this month. See the full list of companies trading below cash on the blog: https://www.stockcalc.com/Blog/stocks-trading-below-cash-value-nas-december-2025
Aclarion $ACON and Adaptimmune Therapeutics $ADAP were trading below cash value on the #NAS this month. See the full list of companies trading below cash: https://www.stockcalc.com/Blog/stocks-trading-below-cash-value-nas-december-2025
Aclarion and Adaptimmune Therapeutics on the NAS were trading below cash value this month. See the full list of companies trading below cash on the blog: https://www.stockcalc.com/Blog/stocks-trading-below-cash-value-nas-december-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.